Changing use of antidiabetic drugs in the UK: Trends in prescribing 2000-2017

BMJ Open

Volumn 8, Issue 7, 2018, Pages

  Wilkinson, Samantha ^a   Douglas, Ian ^a   Stirnadel Farrant, Heide ^b   Fogarty, Damian ^c   Pokrajac, Ana ^d   Smeeth, Liam ^a   Tomlinson, Laurie ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^d WEST HERTFORDSHIRE HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

general diabetes; primary care; public health

Indexed keywords

INSULIN; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HUMAN; INSULIN TREATMENT; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MEDICAL RECORD; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NORTHERN IRELAND; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; TREATMENT OUTCOME; UNITED KINGDOM; WALES; AGED; CLINICAL PRACTICE; COMBINATION DRUG THERAPY; ENGLAND; GLOMERULUS FILTRATION RATE; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PROTOCOL COMPLIANCE; SCOTLAND;

ADULT; AGED; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; ENGLAND; FEMALE; GLOMERULAR FILTRATION RATE; GUIDELINE ADHERENCE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; NORTHERN IRELAND; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PRIMARY HEALTH CARE; SCOTLAND; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; SULFONYLUREA COMPOUNDS; UNITED KINGDOM; WALES;

EID: 85053010058     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2018-022768     Document Type: Article

References (36)

1. National Institute for Health and Care Excellence (NICE). NG28: Type 2 diabetes in adults: management National Institute for Health and Care Excellence, 2015.
2. Healthcare Improvement Scotland. Guideline 154 Pharmacological management of glycaemic control in people with type 2 diabetes. 2017.
3. Montvida O, Shaw J, Atherton JJ, et al. Long-term trends in antidiabetes drug usage in the U. S. : real-world evidence in patients newly diagnosed with type 2 Diabetes. Diabetes Care 2018;41:69-78.
4. Overbeek JA, Heintjes EM, Prieto-Alhambra D, et al. Type 2 diabetes mellitus treatment patterns across europe: A population-based Multidatabase Study. Clin Ther 2017;39:759-70.
5. International Diabetes Federation (IDF). IDF clinical practice recommendations for managing type 2 diabetes in primary care, 2017.
6. American Diabetes Association. Standards of medical care in diabetes-2017. Diabetes Care 2017;40(Suppl 1):S1-S135.
7. Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2016;374:1094.
8. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016;375:323-34.
9. Herrett E, Gallagher AM, Bhaskaran K, et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol 2015;44:827-36.
10. Herrett E, Thomas SL, Schoonen WM, et al. Validation and validity of diagnoses in the General Practice Research Database: A systematic review. Br J Clin Pharmacol 2010;69:4-14.
11. Zoungas S, Woodward M, Li Q, et al. Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes. Diabetologia 2014;57:2465-74.
12. electronic Medicines Compendium (eMC). Summary Product Characteristics: Metformin 500 mg film-coated tablets. 2016. http:// www. medicines. org. uk/ emc/ history/ 23244
13. National Institute for Health and Care Excellence (NICE). NG3: Diabetes in pregnancy. Management from preconception to the postnatal period. 2015.
14. McIntosh AHA, Home PD, Brown F, et al. Clinical guidelines and evidence review for Type 2 diabetes: Blood glucose management. Sheffield: ScHARR, University of Sheffield, 2001.
15. electronic Medicines Compendium (eMC). Summary Product Characteristics: Metformin 500 mg film-coated tablets. http://www. medicines. org. uk/ emc/ medicine/ 32944
16. Health and Social Care Information Centre (HSCIC). Quality and outcomes framework achievement, prevalence and exceptions data, 2012/13: Prescribing and Primary Care Team, 2013.
17. NHS Digital. National Diabetes Audit, 2015-16 Report 2a: Complications and Mortality: National Diabetes Audit (NDA), 2017.
18. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12.
19. Mathur R, Bhaskaran K, Chaturvedi N, et al. Completeness and usability of ethnicity data in UK-based primary care and hospital databases. J Public Health 2014;36:684-92.
20. Benchimol EI, Smeeth L, Guttmann A, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med 2015;12:e1001885.
21. National Institute for Health and Care Excellence (NICE). CG66: Type 2 diabetes: The management of type 2 diabetes. 2008.
22. Stevens PE, de Lusignan S, Farmer CKT, et al. Engaging primary care in CKD initiatives: The UK experience. Nephrology Dialysis Transplantation 2012;27(suppl 3):iii5-iii11.
23. Sharma M, Nazareth I, Petersen I. Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: A retrospective cohort study. BMJ Open 2016;6:e010210.
24. Rafaniello C, Arcoraci V, Ferrajolo C, et al. Trends in the prescription of antidiabetic medications from 2009 to 2012 in a general practice of Southern Italy: A population-based study. Diabetes Res Clin Pract 2015;108:157-63.
25. Hampp C, Borders-Hemphill V, Moeny DG, et al. Use of Antidiabetic Drugs in the U. S., 2003-2012. Diabetes Care 2014;37:1367-74.
26. Evidence-Based Medicine (EBM) DataLab. OpenPrescribing. net: University of Oxford. 2017;2017.
27. Patorno E, Gopalakrishnan C, Bartels DB, et al. Preferential prescribing and utilization trends of diabetes medications among patients with renal impairment: Emerging role of linagliptin and other dipeptidyl peptidase 4 inhibitors. Endocrinology, Diabetes & Metabolism 2018;1:e00005.
28. Muller C, Dimitrov Y, Imhoff O, et al. Oral antidiabetics use among diabetic type 2 patients with chronic kidney disease. Do nephrologists take account of recommendations J Diabetes Complications 2016;30:675-80.
29. Gentile S, Piscitelli P, Viazzi F, et al. Antihyperglycemic treatment in patients with type 2 diabetes in Italy: The impact of age and kidney function. Oncotarget 2017;8:62039-48.
30. Scoggins AT, Ling J, Rabinovich L. Prescribing in primary care: Understanding what shapes GP's prescribing choices and how might these be changed: RAND PftNAOb, 2006.
31. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
32. NHS Digital. Rising cost of drugs for diabetes approaches 1 billion per year [press release]. 2016 http:// content. digital. nhs. uk/ article/ 7327/ Rising-cost-of-drugs-for-diabetes-approaches-1-billion-peryear.
33. National Institute for Health and Care Excellence (NICE). TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes, 2016.
34. National Institute for Health and Care Excellence (NICE). CG87: Type 2 diabetes: The management of type 2 diabetes. 2009.
35. European Medicines Agency recommends suspension of Avandia, Avandmet and Avaglim, 2010.
36. Update on ongoing European review of pioglitazone-containing medicines. Suspension of use of these medicines in France while Europe-wide review continues, 2011.